Sarepta Therapeutics Inc (SRPT)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Edward M. Kaye
Employees:
499
215 FIRST STREET, SUITE 415, CAMBRIDGE, MA 02142
617-274-4000

Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious, and other diseases. It focuses on the development of its potentially disease-modifying DMD drug candidates. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 5.86 Billion Shares Outstanding87.077 Million Avg 30-day Volume 1.339 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.6
Price to Revenue10.3438 Debt to Equity2.2531 EBITDA-603.115 Million
Price to Book Value12.7953 Operating Margin-104.52289999999999 Enterprise Value5.573 Billion
Current Ratio5.33 EPS Growth-0.143 Quick Ratio4.364
1 Yr BETA 0.8716 52-week High/Low 101.24 / 61.31 Profit Margin-105.7307
Operating Cash Flow Growth-343.0217 Altman Z-Score0.3565 Free Cash Flow to Firm -614.16 Million
View SEC Filings from SRPT instead.

View recent insider trading info

Sarepta Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding SRPT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SRPT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

6 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BEHRENS M KATHLEEN

  • Director
 145,517 2021-12-15 3

GRAY MARY ANN

  • Director
 9,403 2021-12-10 2

RODINO-KLAPAC LOUISE HEAD OF R&D, CSO

  • Officer
 65,678 2021-11-24 4

INGRAM DOUGLAS S PRESIDENT & CEO

  • Officer
  • Director
 365,082 2021-11-17 2

MAYO STEPHEN

  • Director
 0 2021-11-16 2

ESTEPAN IAN MICHAEL CHIEF FINANCIAL OFFICER

  • Officer
 26,753 2021-09-08 3

BROWN RYAN EDWARD SVP, GENERAL COUNSEL

  • Officer
 19,368 2021-06-01 4

WIGZELL HANS LENNART RUDOLF

  • Director
 16,518 2021-03-08 2

MARTIN JOHN C

  • Director
 13,431 2021-03-03 1

BARRY RICHARD

  • Director
 3,130,884 2021-03-03 1

NICAISE CLAUDE

  • Director
 17,370 2021-03-03 1

O'NEILL GILMORE NEIL EVP, R&D & CMO

  • Officer
 89,070 2021-03-03 2

CIAMBRONE WILLIAM EVP

  • Officer
 75,000 2021-03-03 1

BRATICA JOSEPH PRINCIPAL FINANCIAL OFFICER

  • Officer
 No longer subject to file 2020-12-11 0

HOWTON DAVID T EVP, GENERAL COUNSEL

  • Officer
 31,871 2020-06-22 0

MAHATME SANDESH EVP, CFO & CBO

  • Officer
 32,272 2020-05-11 0

BONNEY MICHAEL W

  • Director
 9,126 2020-02-28 0

CUMBO ALEXANDER EVP, CHIEF COMMERCIAL OFFICER

  • Officer
 12,008 2020-02-28 0

O'NEILL GILMORE NEIL EVP, R&D & CMO

O'NEILL GILMORE NEIL EVP, R&D & CMO

  • Officer
 0 2019-03-04 2

RUFF SHAMIM SVP, CHIEF REGULATORY AFFAIRS

  • Officer
 31,936 2018-05-22 0

BASI GURIQBAL S. SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
 0 2018-03-05 0

KAYE EDWARD M. MD

  • Director
 71,229 2017-08-03 0

STEHMAN-BREEN CATHERINE SVP, CHIEF MEDICAL OFFICER

  • Officer
 0 2017-04-03 0

KRESS JEAN-PAUL

  • Director
 2,000 2017-03-10 0

WOOD JOAN VP, HUMAN RESOURCES

  • Officer
 14,926 2016-09-20 0

APHALE JAYANT VP, TECHNICAL OPERATIONS

  • Officer
 No longer subject to file 2016-09-19 0

PRICE BEN GIL

  • Director
 42,830 2016-03-14 0

GOOLSBEE WILLIAM ALDEN

  • Director
 8,166 2016-02-29 0

HODGMAN JOHN

  • Director
 6,333 2015-02-27 0

CHASE ANTHONY R

  • Director
 67,194 2015-02-27 0

CHRISTOPHER NISHAN GARABEDIAN PRESIDENT AND CEO

  • Officer
  • Director
 402,552 2015-02-27 0

KRIEG ARTHUR M SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
 0 2014-01-13 0

MARTIGNETTI ANTHONY

  • SEE REMARKS
 0 2013-06-04 0

JACOBSEN MICHAEL A VP OF FINANCE AND PAO

  • Officer
 7,500 2012-08-23 0

MILE MELINDA G CONTROLLER AND PAO

  • Officer
 0 2011-08-31 0

TOSHAV BRACHA EPHRAT SR VP & GENERAL COUNSEL

  • Officer
 0 2011-08-31 0

LINSLEY PETER S SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
 0 2011-05-16 0

BOYLE J DAVID II CEO

  • Officer
 70,282 2010-08-27 0

WELLER DWIGHT D SR. VP CHEMISTRY & MFG.

  • Officer
 0 2010-08-23 0

IVERSEN PATRICK L SR VP OF RESEARCH & DEVLOPMENT

  • Officer
 0 2010-08-23 0

SHREWSBURY STEPHEN B SVP/REGULATORY AFFAIRS

  • Officer
 0 2010-08-23 0

MEDEIROS PAUL SVP BUSINESS DEVELOPMENT

  • Officer
 0 2010-08-23 0

JOHNSON GRAHAM SR VP PRECLINICAL DEV & RSRCH

  • Officer
 0 2010-08-23 0

HUDSON LESLIE FORMER CEO

  • Officer
  • FORMER CEO
 384,559 2010-07-30 0

HAYWOOD GEORGE WEAVER

HAYWOOD CHERYL

  • MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER
 8,329,126 2010-03-16 0

ROCKALL EMERGING MARKETS MASTER FUND LTD

O'DRISCOLL CONOR

EGAN CON

MELDRUM ASSET MANAGEMENT, LLC

  • MAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBERMAY BE DEEMED 10% GROUP MEMBER
 2,935,696 2010-03-16 0

EASTBOURNE CAPITAL MANAGEMENT LLC/CA

  • 10% Owner
 No longer subject to file 2010-03-04 0

KOLE RYSZARD SVP/DISCOVERY RESEARCH

  • Officer
 1,862,926 2010-02-09 0

HAYWOOD GEORGE WEAVER

  • SEE REMARKS BELOW
 No longer subject to file 2009-08-21 0

BLACK BEAR OFFSHORE MASTER FUND LP

  • 10% Owner
 9,914,211 2009-05-31 0

FORREST K MICHAEL OUTSIDE DIRECTOR

  • Officer
  • Director
 15,000 2009-05-19 0

CASEY MICHAEL D

  • Director
 0 2009-05-19 0

HENNEY CHRISTOPHER S

  • Director
 0 2009-03-31 0

FARA JOHN W PHD

  • Director
  • DIRECTOR
 500 2008-05-20 0

OHANLEY PETER D SR. VICE PRESIDENT

  • Officer
 0 2008-02-28 0

WEBBER MARK MILES CFO

  • Officer
 15,446 2008-02-02 0

TIMMINS ALAN P PRESIDENT & COO

  • Officer
 71,382 2008-02-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BEHRENS M KATHLEEN - Director

2021-12-16 20:00:30 -0500 2021-12-15 M 5,000 d 0 direct

BEHRENS M KATHLEEN - Director

2021-12-16 20:00:30 -0500 2021-12-15 M 5,000 $10.08 a 135,517 direct 1.2628 4.2435 4.2435 6 0.0 1

GRAY MARY ANN - Director

2021-12-14 20:02:30 -0500 2021-12-10 M 967 a 9,403 direct -0.5382 4.0536 4.3513 5 -0.5382 2

GRAY MARY ANN - Director

2021-12-14 20:02:30 -0500 2021-12-10 M 967 d 0 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 22:15:03 UTC -0.253 0.323 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 21:45:03 UTC -0.253 0.323 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 21:15:03 UTC -0.253 0.323 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 20:45:03 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 20:15:04 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 19:45:04 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 19:15:03 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 18:45:04 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 18:15:03 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 17:45:03 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 17:15:04 UTC -0.2503 0.3203 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 16:45:03 UTC -0.2521 0.3221 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 16:15:03 UTC -0.2521 0.3221 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 15:45:04 UTC -0.2521 0.3221 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 15:15:03 UTC -0.2521 0.3221 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 14:45:03 UTC -0.2417 0.3117 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 14:15:03 UTC -0.2417 0.3117 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 13:45:03 UTC -0.2417 0.3117 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 13:15:03 UTC -0.2417 0.3117 2200000
SAREPTA THERAPEUTICS INC SRPT 2022-01-24 12:45:04 UTC -0.2417 0.3117 2100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund SRPT -968.0 shares, $-124910.72 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund SRPT -705.0 shares, $-90973.2 2019-12-31 N-PORT
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund SRPT -2819.0 shares, $-212327.08 2019-09-30 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund SRPT -22.0 shares, $-3089.46 2020-09-30 N-PORT
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund SRPT -9436.0 shares, $-710719.52 2019-09-30 N-PORT
Jackson Variable Series Trust- JNL/Nicholas Convertible Arbitrage Fund SRPT -9960.0 shares, $-974287.2 2020-03-31 N-PORT
FundVantage Trust- Gotham Enhanced Index Plus Fund SRPT -47.0 shares, $-4597.54 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund SRPT -33.0 shares, $-3228.06 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund SRPT -87.0 shares, $-8510.34 2020-03-31 N-PORT
INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund SRPT -854.0 shares, $-63648.62 2021-03-31 N-PORT
GMO TRUST- GMO Implementation Fund SRPT -93700.0 shares, $-7319844.0 2021-08-31 N-PORT
GMO TRUST- GMO Benchmark-Free Fund SRPT -33600.0 shares, $-2624832.0 2021-08-31 N-PORT
GMO TRUST- GMO Strategic Opportunities Allocation Fund SRPT -5800.0 shares, $-453096.0 2021-08-31 N-PORT
GMO TRUST- GMO Alternative Allocation Fund SRPT -5000.0 shares, $-390600.0 2021-08-31 N-PORT
AdvisorShares Trust- AdvisorShares Dorsey Wright Short ETF SRPT -3151.0 shares, $-291404.48 2021-09-30 N-PORT
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund SRPT -800.0 shares, $-73984.0 2021-09-30 N-PORT
Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund SRPT -4250.0 shares, $-393040.0 2021-09-30 N-PORT
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio SRPT -12700.0 shares, $-1174496.0 2021-09-30 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund SRPT -1260.0 shares, $-116524.8 2021-09-30 N-PORT
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund SRPT -207500.0 shares, $-16419475.0 2021-10-31 N-PORT
VANGUARD TRUSTEES' EQUITY FUND- VANGUARD ALTERNATIVE STRATEGIES FUND SRPT -1505.0 shares, $-119090.65 2021-10-31 N-PORT

Elevate your investments